NO994027L - Polymorf av zopolrestat-monohydrat - Google Patents

Polymorf av zopolrestat-monohydrat

Info

Publication number
NO994027L
NO994027L NO994027A NO994027A NO994027L NO 994027 L NO994027 L NO 994027L NO 994027 A NO994027 A NO 994027A NO 994027 A NO994027 A NO 994027A NO 994027 L NO994027 L NO 994027L
Authority
NO
Norway
Prior art keywords
zopolrestat monohydrate
zopolrestat
monohydrate
preparation
relates
Prior art date
Application number
NO994027A
Other languages
English (en)
Norwegian (no)
Other versions
NO994027D0 (no
Inventor
John Francis Lambert
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO994027D0 publication Critical patent/NO994027D0/no
Publication of NO994027L publication Critical patent/NO994027L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
NO994027A 1998-08-21 1999-08-20 Polymorf av zopolrestat-monohydrat NO994027L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (2)

Publication Number Publication Date
NO994027D0 NO994027D0 (no) 1999-08-20
NO994027L true NO994027L (no) 2000-02-22

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994027A NO994027L (no) 1998-08-21 1999-08-20 Polymorf av zopolrestat-monohydrat

Country Status (31)

Country Link
US (1) US6159976A (fr)
EP (1) EP0982306A3 (fr)
JP (1) JP2000072769A (fr)
KR (1) KR20000017411A (fr)
CN (1) CN1245804A (fr)
AP (1) AP9901662A0 (fr)
AU (1) AU4453299A (fr)
BG (1) BG103674A (fr)
BR (1) BR9903873A (fr)
CA (1) CA2280590A1 (fr)
EA (1) EA199900675A3 (fr)
EE (1) EE9900385A (fr)
GT (1) GT199900137A (fr)
HR (1) HRP990259A2 (fr)
HU (1) HUP9902783A3 (fr)
ID (1) ID23307A (fr)
IL (1) IL131419A0 (fr)
IS (1) IS5155A (fr)
MA (1) MA26678A1 (fr)
NO (1) NO994027L (fr)
NZ (1) NZ337363A (fr)
OA (1) OA11150A (fr)
PA (1) PA8480601A1 (fr)
PE (1) PE20000993A1 (fr)
PL (1) PL335016A1 (fr)
SG (1) SG83147A1 (fr)
TN (1) TNSN99159A1 (fr)
TR (1) TR199901996A2 (fr)
UY (1) UY25668A1 (fr)
YU (1) YU39899A (fr)
ZA (1) ZA995297B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221430T1 (hr) 2010-07-16 2023-01-06 The Trustees Of Columbia University In The City Of New York Inhibitori aldozoreduktaze i njihova uporaba
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2014126885A1 (fr) * 2013-02-13 2014-08-21 Mylari Banavara L Sels solubles dans l'eau d'inhibiteurs d'aldose réductase pour le traitement de complications diabétiques
RS61239B1 (sr) 2016-06-21 2021-01-29 Univ Columbia Inhibitori aldozne reduktaze i postupci korišćenja
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CA3132136A1 (fr) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibiteurs de l'aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
EP4125909A1 (fr) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Inhibiteurs d'aldose réductase pour le traitement du syndrome de détresse respiratoire aiguë, d'une inflammation/lésion pulmonaire aiguë, d'une lésion cardiaque et pour une thérapie antivirale
WO2021222165A1 (fr) 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Inhibiteurs d'aldose réductase pour le traitement d'une déficience en sorbitol déshydrogénase
US20230322786A1 (en) * 2020-09-08 2023-10-12 Teva Pharmaceuticals International Gmbh Solid state forms of at-001 and process for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (fr) * 1990-08-28 1992-03-05 Pfizer Inc. Monohydrate d'acide 3-(5-trifluoromethylbenzothiazol-2-ylmethyle)-4-oxo-3h-phytalazine-1-ylacetique
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
YU39899A (sh) 2002-12-10
BG103674A (en) 2000-03-31
EP0982306A3 (fr) 2000-07-05
US6159976A (en) 2000-12-12
EA199900675A2 (ru) 2000-02-28
ZA995297B (en) 2001-02-19
PA8480601A1 (es) 2000-09-29
AU4453299A (en) 2000-03-09
NZ337363A (en) 2001-01-26
SG83147A1 (en) 2001-09-18
EP0982306A2 (fr) 2000-03-01
HUP9902783A2 (hu) 2000-12-28
AP9901662A0 (en) 1999-09-30
CA2280590A1 (fr) 2000-02-21
BR9903873A (pt) 2000-09-19
MA26678A1 (fr) 2004-12-20
PE20000993A1 (es) 2000-10-04
NO994027D0 (no) 1999-08-20
HUP9902783A3 (en) 2001-01-29
ID23307A (id) 2000-04-05
HU9902783D0 (en) 1999-10-28
TNSN99159A1 (fr) 2005-11-10
IS5155A (is) 2000-02-22
EA199900675A3 (ru) 2000-06-26
TR199901996A2 (xx) 2000-03-21
EE9900385A (et) 2000-04-17
UY25668A1 (es) 2001-08-27
CN1245804A (zh) 2000-03-01
GT199900137A (es) 2001-02-09
PL335016A1 (en) 2000-02-28
HRP990259A2 (en) 2000-06-30
JP2000072769A (ja) 2000-03-07
IL131419A0 (en) 2001-01-28
OA11150A (en) 2003-04-16
KR20000017411A (ko) 2000-03-25

Similar Documents

Publication Publication Date Title
FI104790B (fi) Menetelmä aktivoidun proteiini C:n valmistamiseksi
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
NO20081211L (no) Xantinderivater som selektive HM74A agonister
NO994027L (no) Polymorf av zopolrestat-monohydrat
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
NO20081633L (no) Lav hygroskopisk Aripiprazol medikament forbindelse og fremgangsmate for fremstilling derav
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
WO2006096444A3 (fr) Composes chimiques
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
WO2002040484A3 (fr) Nouveaux derives imidazole, procede de production correspondant et utilisation de ces derives
WO2003015715A3 (fr) Derives de tetrahydroquinoline utilises comme agents antithrombotiques
YU62504A (sh) Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
WO2002008226A3 (fr) Composants pyridone-2 tricycliques servant d'inhibiteurs de la transcriptase inverse du hiv
WO2001051489A3 (fr) Procedes pour abaisser les niveaux d'acide urique
AR022130A1 (es) Nuevos derivados de arilalcanoilo, los procesos para su preparacion, uso y las composiciones farmaceuticas que los contienen
Schmid et al. Hypochlorite-oxidized low density lipoproteins reduce production and bioavailability of nitric oxide in RAW 264.7 macrophages by distinct mechanisms
WO2004072037A8 (fr) Derives de 2,3'-bipyridines servant d'inhibiteurs de cox-2 selectifs
BRPI0410390A (pt) compostos; processo para a preparação de compostos; composições farmacêuticas; método para o tratamento e/ou prevenção de doenças e uso destes compostos
WO2003011119A3 (fr) Procedes et compositions pour le diagnostic et le traitement d'etats vasculaires
MA29372B1 (fr) Nouveaux composes derives du 5-thioxylose et leur utilisation therapeutique
BR0113350A (pt) Aminoalquenilbenzoil-benzofuranos ou benzotiofenos, seu processo de preparação e as composições que os contêm
JPH08134090A (ja) ガラクトシルコウジ酸、その製造法およびそれを含有するチロシナーゼ阻害剤
DE602004027629D1 (de) d-(17alpha)-13-ETHYL-17HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE IN FORM DES REINEN 3E- UND 3Z-OXIMES SOWIE DAS VERFAHREN ZUR HERSTELLUNG DER MISCHU

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application